Category Intelligence on In-Vivo Toxicology Testing covers the following
The global pre-clinical toxicology market size is estimated at $4.4-4.5 billion in 2017, with a CAGR of about 6.5-7% percent. The current outsourcing penetration for toxicology services is over 50 percent, and will increase by ~2–3 percent annually, over the next five years. The market is dominated by a few service providers like Charles River Laboratories, Covance, Envigo, MPI research, etc
The in-vivo toxicology studies show that the in-vivo toxicology market has a growth rate: 6-7 percent CAGR between 2015 and 2022 and the 2017 Market Value: $4.5 Billion. According to pharma analysis toxicological studies in vitro, the regional revenue split is North America: 50–55 percent, Europe: 30–32 percent, Asia:15–20 percent, U.S. was expected to dominate the in-vivo toxicology testing market in 2017. Increased protest against animals used in pharma research have led to numerous technologies offering alternatives to animal testing. Also, regulatory compliances mandate that service providers restrict the number of in-vivo models, through the application of the 3R principle. The key in vivo toxicology suppliers are Charles River Laboratories, Envigo, Evotec, Labcorp, Eurofins, and Ricerca.
Increased protest against animals used in pharma research have led to numerous technologies offering alternatives to animal testing. Also, regulatory compliances mandate that service providers restrict the number of in-vivo models, through the application of the 3R principle
Agrochemical Industry Demand
Strategic deals involving lift-out in preclinical toxicology services by the pharmaceutical companies would increase, in contrast to the current scenario, where the widely adopted (45 percent) engagement model is project by project, as it would help in reducing their fixed cost by shutting down or transferring the toxicology facilities that are under-utilized
Engagement Model Adoption: 2016
In vivo toxicology services is a highly fragmented supply tail, giving sponsors high bargaining power. Service providers, on the other hand, provides allied and proactive services to their sponsors, to differentiate among themselves in the in vivo toxicology market. According to in vivo toxicology studies, industrial competition is expected to further increase, as suppliers differentiate themselves with the service (alternatives/technology) capabilities they offer. Threat of substitutes will be extremely low in the market, as alternate testing methods have not replaced in-vivo testing fully, and are at best seen as supplements only. The in vivo toxicology market is highly characterized by early stage attrition, and increased regulatory mandates. Also, the usage of in-vitro and in-silico technologies in ADME and toxicology are the latest trends.
Complimentary 12-month access to Beroe LiVE
COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)